Aumolertinib With or Without Chemotherapy as 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Sensitizing EGFR Mutations

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
To assess the efficacy and safety of Aumolertinib plus chemotherapy versus Aumolertinib alone as first-line treatment in locally advanced or metastatic non-small cell lung cancer (NSCLC) with sensitizing epidermal growth factor receptor mutations (EGFRm+).
Epistemonikos ID: 8096b01bbf4cf2067e4d5e898c17645a224957ae
First added on: May 09, 2024